Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Nanjing Hicin Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, particularly in the oncology and cardiovascular sectors. The company has a strong foothold in the Chinese market and is expanding its product offerings, which include over 100 formulations, leveraging its high gross margins to invest in R&D and market expansion.
Hicin generates revenue primarily through the sale of generic and specialty drugs, benefiting from high gross margins of 82.5%. The company maintains pricing power through its established brand reputation and regulatory approvals, allowing it to compete effectively in the growing Chinese pharmaceutical market.
Approval of new drug formulations by the National Medical Products Administration (NMPA)
Market share growth in oncology and cardiovascular segments
Changes in government healthcare policies affecting drug pricing
Fluctuations in raw material costs impacting production expenses
Regulatory changes affecting drug approval processes
Technological disruption in drug development and manufacturing
Intense competition from domestic and international generic manufacturers
Potential entry of new players in the oncology market
Moderate liquidity risk due to a current ratio of 1.07
Potential for increased debt if expansion plans require significant capital
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP fluctuations.
Interest rates impact Hicin's financing costs for R&D and expansion. Higher rates could increase borrowing costs, affecting profitability and valuation multiples.
minimal - The company's low debt-to-equity ratio of 0.28 indicates limited reliance on credit.
growth - Investors are likely attracted to Hicin due to its high revenue growth rate of 33% YoY and potential for further expansion in the pharmaceutical market.
moderate - The stock has shown significant volatility with a 1-year return of -23.2%, indicating sensitivity to market conditions and company performance.
